Anna Franzone1, Thomas Pilgrim1, Stefan Stortecky1, Stephan Windecker2. 1. Department of Cardiology, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. 2. Department of Cardiology, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. stephan.windecker@insel.ch.
Abstract
PURPOSE OF REVIEW: The purpose of this review was to summarize recent progress in the field of transcatheter aortic valve replacement (TAVR), discuss expansion of indications, and identify areas of future clinical applications. RECENT FINDINGS: Favorable clinical outcomes as well as continued refinement of transcatheter heart valve technology have prompted the continuous expansion of indications for TAVR. The results of randomized clinical trials comparing the safety and efficacy of TAVR relative to conventional surgical aortic valve replacement (SAVR) in lower- than high-risk patients have recently been published, and trials among lower-risk categories are ongoing. Furthermore, evidence of the feasibility and safety of TAVR in patients with other pathological conditions is accumulating. Large pivotal randomized studies support the extension of TAVR to intermediate-risk patients. Moreover, TAVR is emerging as a valuable treatment option for other categories including patients with bicuspid aortic valve, those with pure native aortic regurgitation deemed inoperable, and those with degenerated surgical bioprosthetic valves.
PURPOSE OF REVIEW: The purpose of this review was to summarize recent progress in the field of transcatheter aortic valve replacement (TAVR), discuss expansion of indications, and identify areas of future clinical applications. RECENT FINDINGS: Favorable clinical outcomes as well as continued refinement of transcatheter heart valve technology have prompted the continuous expansion of indications for TAVR. The results of randomized clinical trials comparing the safety and efficacy of TAVR relative to conventional surgical aortic valve replacement (SAVR) in lower- than high-risk patients have recently been published, and trials among lower-risk categories are ongoing. Furthermore, evidence of the feasibility and safety of TAVR in patients with other pathological conditions is accumulating. Large pivotal randomized studies support the extension of TAVR to intermediate-risk patients. Moreover, TAVR is emerging as a valuable treatment option for other categories including patients with bicuspid aortic valve, those with pure native aortic regurgitation deemed inoperable, and those with degenerated surgical bioprosthetic valves.
Authors: G Michael Deeb; Michael J Reardon; Stan Chetcuti; Himanshu J Patel; P Michael Grossman; Steven J Yakubov; Neal S Kleiman; Joseph S Coselli; Thomas G Gleason; Joon Sup Lee; James B Hermiller; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John Conte; Jon Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; David H Adams; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2016-04-03 Impact factor: 24.094
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith Journal: Lancet Date: 2015-03-15 Impact factor: 79.321
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-10-09 Impact factor: 24.094
Authors: George C M Siontis; Peter Jüni; Thomas Pilgrim; Stefan Stortecky; Lutz Büllesfeld; Bernhard Meier; Peter Wenaweser; Stephan Windecker Journal: J Am Coll Cardiol Date: 2014-07-15 Impact factor: 24.094
Authors: Danny Dvir; John G Webb; Sabine Bleiziffer; Miralem Pasic; Ron Waksman; Susheel Kodali; Marco Barbanti; Azeem Latib; Ulrich Schaefer; Josep Rodés-Cabau; Hendrik Treede; Nicolo Piazza; David Hildick-Smith; Dominique Himbert; Thomas Walther; Christian Hengstenberg; Henrik Nissen; Raffi Bekeredjian; Patrizia Presbitero; Enrico Ferrari; Amit Segev; Arend de Weger; Stephan Windecker; Neil E Moat; Massimo Napodano; Manuel Wilbring; Alfredo G Cerillo; Stephen Brecker; Didier Tchetche; Thierry Lefèvre; Federico De Marco; Claudia Fiorina; Anna Sonia Petronio; Rui C Teles; Luca Testa; Jean-Claude Laborde; Martin B Leon; Ran Kornowski Journal: JAMA Date: 2014-07 Impact factor: 56.272
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245